Collectively, our results demonstrated that STC2 promoted metastasis and glycolysis traits by regulating ITGB2/FAK/SOX6 axis, and suggest that the signaling axis might provide a novel therapeutic target for the inhibition of NPC progression and metastasis. This evidence concerns the gene SOX6 and nasopharyngeal carcinoma.